Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $43,400.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $8.68, for a total transaction of $43,400.00. Following the completion of the transaction, the insider directly owned 213,387 shares of the company’s stock, valued at approximately $1,852,199.16. This trade represents a 2.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

• On Wednesday, August 12th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.52, for a total transaction of $37,600.00.
• On Monday, July 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.66, for a total value of $28,300.00.
• On Monday, July 13th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total value of $28,500.00.
• On Monday, July 6th, Philippe Menu sold 7,393 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.16, for a total value of $38,147.88.
• On Thursday, June 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.50, for a total value of $27,500.00.

SOPHiA GENETICS Trading Down 8.7%

Shares of SOPH opened at $8.14 on Friday. SOPHiA GENETICS SA has a twelve month low of $3.10 and a twelve month high of $8.98. The stock has a market cap of $682.86 million, a PE ratio of -7.08 and a beta of 0.96. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. The business’s 50-day moving average price is $6.52 and its 200-day moving average price is $5.45.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The firm had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. On average, equities analysts forecast that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on SOPH shares. BTIG Research lifted their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. HC Wainwright upped their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $10.00.

Institutional Trading of SOPHiA GENETICS

Several hedge funds have recently added to or reduced their stakes in the business. Perkins Capital Management Inc. purchased a new stake in SOPHiA GENETICS during the fourth quarter valued at about $49,000. Squarepoint Ops LLC purchased a new position in shares of SOPHiA GENETICS in the third quarter worth about $49,000. First Dallas Securities Inc. purchased a new position in shares of SOPHiA GENETICS in the first quarter worth about $50,000. Quadrature Capital Ltd bought a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at about $54,000. Finally, XTX Topco Ltd bought a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at about $55,000. 31.59% of the stock is owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.